Research ArticleInfectious Disease

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

See allHide authors and affiliations

Science Translational Medicine  03 May 2017:
Vol. 9, Issue 388, eaaj1928
DOI: 10.1126/scitranslmed.aaj1928

Log in to view full text

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine

Navigate This Article